BACKGROUND: Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations. However, the number of PIK3CA-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with PIK3CA-mutated CRC. PATIENTS AND METHODS: Patients with PIK3CA-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, PIK3CA mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression. RESULTS: From a cohort of 1487 CRC patients, 185 patients harbored a PIK3CA mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34-92) and median follow up was 54 months. Forty-nine (26%) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant. CONCLUSIONS: Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.
BACKGROUND: Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations. However, the number of PIK3CA-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with PIK3CA-mutated CRC. PATIENTS AND METHODS: Patients with PIK3CA-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, PIK3CA mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression. RESULTS: From a cohort of 1487 CRC patients, 185 patients harbored a PIK3CA mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34-92) and median follow up was 54 months. Forty-nine (26%) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant. CONCLUSIONS: Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.
Authors: Bernard F Cole; Richard F Logan; Susan Halabi; Robert Benamouzig; Robert S Sandler; Matthew J Grainge; Stanislas Chaussade; John A Baron Journal: J Natl Cancer Inst Date: 2009-02-10 Impact factor: 13.506
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Enric Domingo; David N Church; Oliver Sieber; Rajarajan Ramamoorthy; Yoko Yanagisawa; Elaine Johnstone; Brian Davidson; David J Kerr; Ian P M Tomlinson; Rachel Midgley Journal: J Clin Oncol Date: 2013-09-23 Impact factor: 44.544
Authors: Marlies S Reimers; Esther Bastiaannet; Ruth E Langley; Ronald van Eijk; Ronald L P van Vlierberghe; Valery E P Lemmens; Myrthe P P van Herk-Sukel; Tom van Wezel; Riccardo Fodde; Peter J K Kuppen; Hans Morreau; Cornelis J H van de Velde; Gerrit Jan Liefers Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Gregory A Roth; Catherine W Gillespie; Ali A Mokdad; Danny D Shen; David W Fleming; Andy Stergachis; Christopher J L Murray; Ali H Mokdad Journal: BMC Cardiovasc Disord Date: 2014-02-07 Impact factor: 2.298
Authors: Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak Journal: J Mol Diagn Date: 2017-02-06 Impact factor: 5.568
Authors: Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Danny A Milner; Reiko Nishihara Journal: Annu Rev Pathol Date: 2018-08-20 Impact factor: 23.472
Authors: Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak Journal: Am J Clin Pathol Date: 2017-02-03 Impact factor: 2.493
Authors: Akihiro Nishi; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Andy S Tan; Ichiro Kawachi; Shuji Ogino Journal: Expert Rev Mol Diagn Date: 2015-12-04 Impact factor: 5.225
Authors: Jane C Figueiredo; Eric J Jacobs; Christina C Newton; Mark A Guinter; William G Cance; Peter T Campbell Journal: J Natl Cancer Inst Date: 2021-07-01 Impact factor: 13.506
Authors: Peter C Elwood; Gareth Morgan; Janet E Pickering; Julieta Galante; Alison L Weightman; Delyth Morris; Mark Kelson; Sunil Dolwani Journal: PLoS One Date: 2016-04-20 Impact factor: 3.240
Authors: Ronan T Gray; Marie M Cantwell; Helen G Coleman; Maurice B Loughrey; Peter Bankhead; Stephen McQuaid; Roisin F O'Neill; Kenneth Arthur; Victoria Bingham; Claire McGready; Anna T Gavin; Chris R Cardwell; Brian T Johnston; Jacqueline A James; Peter W Hamilton; Manuel Salto-Tellez; Liam J Murray Journal: Clin Transl Gastroenterol Date: 2017-04-27 Impact factor: 4.488